Vasopressin: a new target for the treatment of heart failure
- 31 July 2003
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 146 (1), 9-18
- https://doi.org/10.1016/s0002-8703(02)94708-3
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of HyponatremiaThe American Journal of Cardiology, 2006
- An Overview of SR121463, a Selective Non‐Peptide Vasopressin V2 Receptor AntagonistCardiovascular Drug Reviews, 2001
- Hormones and Hemodynamics in Heart FailureThe New England Journal of Medicine, 1999
- Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.JCI Insight, 1996
- Arginine vasopressin and the renal response to water loading in congestive heart failureThe American Journal of Cardiology, 1986
- Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man.JCI Insight, 1986
- Role of Intracerebral Angiotensin Receptors in the Regulation of Vasopressin Release and the Cardiovascular SystemNeuroendocrinology, 1986
- Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failureThe American Journal of Cardiology, 1985
- Increased plasma arginine vasopressin levels in patients with congestive heart failureJournal of the American College of Cardiology, 1983
- Radioimmunoassay of Plasma Arginine Vasopressin in Hyponatremic Patients with Congestive Heart FailureThe New England Journal of Medicine, 1981